OnKure Therapeutics, Inc. (OKUR) Investor Relations Documents

OnKure Therapeutics, Inc. (OKUR) investor relations documents from the company's IR site: 3 presentations, 13 press releases; latest deck 2026-08-05. Read in-app with summaries. First-party data.

Corporate Overview August 2026: OnKure Therapeutics' PI3Kα inhibitors OKI-355 (Vascular Anomalies) and OKI-345 (Cancer) target pan-mutant sites. $176M cash funds operations into 2029.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-05	Presentation	Corporate Overview August 2026
2026-08-04	Press release	OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-07-15	Presentation	KOL Event Material_2026.07.15.pdf
2026-07-02	Press release	OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant All
2026-05-05	Press release	OnKure Therapeutics Reports First Quarter 2026 Financial Results
2026-03-27	Press release	OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant
2026-03-12	Press release	PDF Version
2026-03-12	Press release	OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2025-11-06	Press release	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update
2025-11-04	Press release	OnKure Therapeutics to Participate in Upcoming Investor Conferences
2025-08-12	Press release	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
2025-05-06	Press release	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
2025-03-10	Press release	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
2025-03-04	Press release	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
2024-12-10	Press release	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIK
2024-12-10	Presentation	2024.12.10_OKUR_Management Call_(SABCS 2024)_FINAL.pdf

OKUR overview · OKUR earnings · OKUR financials · OKUR KPIs · OKUR ownership · OKUR peers · OKUR filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.